The Efficacy and Safety of Rituximab in a Patient with Rheumatoid Spondylitis

Rheumatoid arthritis (RA) is considered as a connective tissue disease while ankylosing spondylitis (AS) is a prototype of spondyloarthritis. These diseases are seen concomitantly only very rarely. Also, rituximab has proven efficacy in the treatment of RA while its role in the treatment of AS is un...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobak, Şenol, Karaarslan, Ahmet, Oksel, Fahrettin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3845512/
https://www.ncbi.nlm.nih.gov/pubmed/24324911
http://dx.doi.org/10.1155/2013/792526
_version_ 1782293317475631104
author Kobak, Şenol
Karaarslan, Ahmet
Oksel, Fahrettin
author_facet Kobak, Şenol
Karaarslan, Ahmet
Oksel, Fahrettin
author_sort Kobak, Şenol
collection PubMed
description Rheumatoid arthritis (RA) is considered as a connective tissue disease while ankylosing spondylitis (AS) is a prototype of spondyloarthritis. These diseases are seen concomitantly only very rarely. Also, rituximab has proven efficacy in the treatment of RA while its role in the treatment of AS is unclear. In this presentation, the concomitant presence of RA and AS in a 43-year-old male patient as well as the efficacy and safety of rituximab is discussed. Rituximab was given due to lack of response to treatment with anti-TNF-alpha. Evaluations made at the 6th and 12th months of treatment showed complete response for RA and partial response for AS.
format Online
Article
Text
id pubmed-3845512
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-38455122013-12-09 The Efficacy and Safety of Rituximab in a Patient with Rheumatoid Spondylitis Kobak, Şenol Karaarslan, Ahmet Oksel, Fahrettin Case Rep Rheumatol Case Report Rheumatoid arthritis (RA) is considered as a connective tissue disease while ankylosing spondylitis (AS) is a prototype of spondyloarthritis. These diseases are seen concomitantly only very rarely. Also, rituximab has proven efficacy in the treatment of RA while its role in the treatment of AS is unclear. In this presentation, the concomitant presence of RA and AS in a 43-year-old male patient as well as the efficacy and safety of rituximab is discussed. Rituximab was given due to lack of response to treatment with anti-TNF-alpha. Evaluations made at the 6th and 12th months of treatment showed complete response for RA and partial response for AS. Hindawi Publishing Corporation 2013 2013-11-12 /pmc/articles/PMC3845512/ /pubmed/24324911 http://dx.doi.org/10.1155/2013/792526 Text en Copyright © 2013 Şenol Kobak et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Kobak, Şenol
Karaarslan, Ahmet
Oksel, Fahrettin
The Efficacy and Safety of Rituximab in a Patient with Rheumatoid Spondylitis
title The Efficacy and Safety of Rituximab in a Patient with Rheumatoid Spondylitis
title_full The Efficacy and Safety of Rituximab in a Patient with Rheumatoid Spondylitis
title_fullStr The Efficacy and Safety of Rituximab in a Patient with Rheumatoid Spondylitis
title_full_unstemmed The Efficacy and Safety of Rituximab in a Patient with Rheumatoid Spondylitis
title_short The Efficacy and Safety of Rituximab in a Patient with Rheumatoid Spondylitis
title_sort efficacy and safety of rituximab in a patient with rheumatoid spondylitis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3845512/
https://www.ncbi.nlm.nih.gov/pubmed/24324911
http://dx.doi.org/10.1155/2013/792526
work_keys_str_mv AT kobaksenol theefficacyandsafetyofrituximabinapatientwithrheumatoidspondylitis
AT karaarslanahmet theefficacyandsafetyofrituximabinapatientwithrheumatoidspondylitis
AT okselfahrettin theefficacyandsafetyofrituximabinapatientwithrheumatoidspondylitis
AT kobaksenol efficacyandsafetyofrituximabinapatientwithrheumatoidspondylitis
AT karaarslanahmet efficacyandsafetyofrituximabinapatientwithrheumatoidspondylitis
AT okselfahrettin efficacyandsafetyofrituximabinapatientwithrheumatoidspondylitis

Ejemplares similares